On Thursday 16 April 2026, the Covid-19 Inquiry published its fourth report, which focused on the role of vaccines and therapeutics throughout the pandemic and put forward five recommendations for the Government to consider. Today, the Government published their response and set out the actions we are taking to address them.
Our thoughts remain with all those affected by the pandemic. We recognise the impact that these experiences have had on individuals and families, and the importance of ensuring that their experiences are heard and reflected in the lessons we learn from the inquiry. I also want to recognise all those who served the public with dedication, compassion and courage in the most challenging of conditions.
Baroness Hallett’s module 4 report recognises the remarkable success of the vaccines and therapeutics programmes. Effective vaccines were developed, authorised and deployed at exceptional speed, while still going through the robust clinical trial and safety process necessary for such interventions. Therapeutics were identified quickly to treat those who became seriously ill. The report sets out how vaccines protected many people against the most serious effects of covid-19, saved lives, reduced pressure on healthcare systems and helped to ease the wider social and economic effects of the pandemic.
The report also highlights the factors that made this possible. This includes the UK’s world-leading position in biomedical sciences, the dedication of doctors, scientists and researchers supported by the UK’s academic institutions and research funders, the skills of those managing the programmes, and the staff and volunteers keeping the vaccination centres running. I also want to thank the public for coming forward to be vaccinated to protect those around them.
The Government are also grateful to Baroness Hallet and the Covid-19 Inquiry team for identifying important lessons for the future in relation to planning and responding to future pandemics. This publication sets out our response to the module 4 report and recommendations.
We recognise there is more to do, and we are continuing to learn from the inquiry’s findings and address the issues identified. We must ensure that future vaccination and therapeutics programmes earn people’s trust, are accessible to everyone who needs them and are guided by the best available evidence, as these programmes were. We must continue and build on our work with communities to understand and address the barriers that influence vaccine uptake.
The inquiry notes that safety monitoring must continue to evolve and proposes reform of the vaccine damage payment scheme to ensure it is fair to those seriously harmed or bereaved following vaccination, and recognises the trauma and distress caused to families facing long waits for the processing of their claims. We take these concerns very seriously and will look further at what needs to be done to improve the scheme.